Guiyang Xintian Pharmaceutical Co Ltd (002873) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Guiyang Xintian Pharmaceutical Co Ltd (002873) has a cash flow conversion efficiency ratio of 0.039x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥48.81 Million ≈ $7.14 Million USD) by net assets (CN¥1.26 Billion ≈ $184.86 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 002873 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Guiyang Xintian Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Guiyang Xintian Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Guiyang Xintian Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Guiyang Xintian Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kaplamin Ambalaj Sanayi ve Ticaret AS
IS:KAPLM
|
-0.027x |
|
Zhangjiagang Haiguo New Energy Equipment Manufacturing Co. Ltd.
SHE:301063
|
N/A |
|
SilverBox Corp V
NYSE:SBXE
|
-0.001x |
|
enCore Energy Corp. Common Shares
NYSE MKT:EU
|
-0.073x |
|
Synopex Inc
KQ:025320
|
0.012x |
|
Aluflexpack AG
SW:AFP
|
0.116x |
|
Nacity Property Service Co Ltd
SHG:603506
|
-0.085x |
|
MFS Intermediate Income Trust
NYSE:MIN
|
0.046x |
Annual Cash Flow Conversion Efficiency for Guiyang Xintian Pharmaceutical Co Ltd (2012–2025)
The table below shows the annual cash flow conversion efficiency of Guiyang Xintian Pharmaceutical Co Ltd from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Guiyang Xintian Pharmaceutical Co Ltd stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥1.26 Billion ≈ $183.83 Million |
CN¥83.73 Million ≈ $12.25 Million |
0.067x | -9.64% |
| 2024-12-31 | CN¥1.19 Billion ≈ $174.82 Million |
CN¥88.13 Million ≈ $12.90 Million |
0.074x | +5.59% |
| 2023-12-31 | CN¥1.11 Billion ≈ $162.92 Million |
CN¥77.78 Million ≈ $11.38 Million |
0.070x | +4.05% |
| 2022-12-31 | CN¥1.13 Billion ≈ $165.24 Million |
CN¥75.82 Million ≈ $11.09 Million |
0.067x | -51.90% |
| 2021-12-31 | CN¥890.44 Million ≈ $130.30 Million |
CN¥124.30 Million ≈ $18.19 Million |
0.140x | -34.22% |
| 2020-12-31 | CN¥828.30 Million ≈ $121.21 Million |
CN¥175.77 Million ≈ $25.72 Million |
0.212x | +345.92% |
| 2019-12-31 | CN¥708.76 Million ≈ $103.71 Million |
CN¥33.73 Million ≈ $4.94 Million |
0.048x | -33.95% |
| 2018-12-31 | CN¥660.59 Million ≈ $96.66 Million |
CN¥47.59 Million ≈ $6.96 Million |
0.072x | -27.78% |
| 2017-12-31 | CN¥622.11 Million ≈ $91.03 Million |
CN¥62.06 Million ≈ $9.08 Million |
0.100x | -54.60% |
| 2016-12-31 | CN¥279.21 Million ≈ $40.86 Million |
CN¥61.34 Million ≈ $8.98 Million |
0.220x | +22.08% |
| 2015-12-31 | CN¥226.31 Million ≈ $33.12 Million |
CN¥40.73 Million ≈ $5.96 Million |
0.180x | -8.09% |
| 2014-12-31 | CN¥190.50 Million ≈ $27.88 Million |
CN¥37.30 Million ≈ $5.46 Million |
0.196x | +122.05% |
| 2013-12-31 | CN¥157.38 Million ≈ $23.03 Million |
CN¥13.88 Million ≈ $2.03 Million |
0.088x | -26.49% |
| 2012-12-31 | CN¥178.44 Million ≈ $26.11 Million |
CN¥21.41 Million ≈ $3.13 Million |
0.120x | -- |
About Guiyang Xintian Pharmaceutical Co Ltd
Guiyang Xintian Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of new traditional Chinese medicines in China. The company offers products in various dosage forms, including hard capsules, oral solutions, granules, gels, tablets, syrups, tinctures, lotions, medicated wines, and elixirs. Its products are used for the treatment of … Read more